Kite (a Gilead company) release unpublished data demonstrating the key determinants influencing durable responses in large B cell lymphoma patients treated with YESCARTA CAR-T therapy
Dr. Adrian Bot (VP of Translational Medicine – Kite, a Gilead Company) provides an update on the factors determining durable responses...